Emerging Cancer Vaccines Market to 2017 – Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market

Report Summary

GBI Research, the leading business intelligence provider, has released its latest research, “Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III Pipeline to Shape the Future Cancer Vaccines Market”, which provides insights into the global emerging cancer vaccines market and a market forecast until 2017. The report provides an in-depth analysis of the five therapeutic indications for which vaccines are available in the market or which have a promising vaccine in Phase III of their pipeline. In addition, the report also includes various types of cancer vaccine development and vaccine delivery methods along with a case study, advantages and disadvantages for each type, insights into the cancer vaccines R&D pipeline, SWOT profiles of the vaccine companies, and major Mergers and Acquisitions (M&A), deals and co-developments.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research’s analysis shows that the global cancer vaccines market for cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma was valued at $1,657m in 2010. The market is expected to witness a Compound Annual Growth Rate (CAGR) of 21% for the forecast period (2010-2017) and will reach $6.3 billion by 2017. The market will be driven by the launch of promising Phase III molecules in cervical cancer, lung cancer, pancreatic cancer and melanoma. With patent-protection granted to available vaccines, the market will demonstrate significant growth. Strategic consolidations through M&A, deals and co-developments will provide R&D, marketing, sales and regulatory support in the future and help gain a greater market share.

Scope

• The report provides a market characterization, pipeline analysis and key M&A trends in the cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma vaccines market.
• Descriptive case studies, advantages and disadvantages for various types of cancer vaccine development and vaccine delivery methods
• Data and analysis on the emerging cancer vaccines market
• Annualized market data for the cancer vaccines market, with forecasts to 2017
• Market data on the therapeutic landscape which covers cervical cancer, prostate cancer, lung cancer, pancreatic cancer and melanoma, including market size, market share and annual cost of vaccination
• Key drivers and restraints that have had a significant impact on the market and on each indication
• The competitive landscape of the emerging cancer vaccines market which includes companies such as Merck, Amgen, GlaxoSmithKline, Dendreon
• Key M&A, deals and co-developments that took place from 2004 to 2011 in the global cancer vaccines market

Reasons to buy

The report will enhance your decision-making capability. It will allow you to -

• Familiarize yourself with the different types of cancer vaccine development and vaccine delivery methods available, with case studies and analysis of advantages and disadvantages for a better understanding of the market.
• Align your product portfolio to the markets with high growth potential.
• Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
• Devise a more tailored country strategy through the understanding of key drivers and barriers of each region’s cancer vaccines market.
• Develop key strategic initiatives by understanding the key focus areas and top selling vaccines of leading companies.
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Emerging Cancer Vaccines Market to 2017: Executive Summary
2.1 The Global Cancer Vaccines Market is Forecast to Grow at a CAGR of 21% between 2010 and 2017
2.2 Promising Vaccines to be Launched in Melanoma, Lung and Pancreatic Cancer will Face Less Competition due to Absence of Marketed Vaccines
2.3 Licensing Agreements Form the Major Strategic Consolidations and North America is the Favorite Geographic Destination

3 Emerging Cancer Vaccines Market to 2017: Introduction
3.1 GBI Research Report Guidance

4 Emerging Cancer Vaccines Market to 2017: Cancer Vaccine Development
4.1 Different Approaches to Cancer Vaccine Development
4.1.1 Whole-Cell Cancer Vaccines
4.1.2 Antigen Vaccines
4.1.3 DNA Vaccines
4.1.4 Vector-based Vaccines
4.1.5 Dendritic Cell (DC) Vaccines
4.1.6 Idiotype Vaccines
4.2 Cancer Vaccines in Combination Therapy (Adjuvants)
4.2.1 Microbes
4.2.2 Substances Produced by Bacteria
4.2.3 Biological Products Derived from Non-Microbial Organisms
4.2.4 Non-Biological Substances
4.2.5 Natural or Synthetic Cytokines

5 Emerging Cancer Vaccines Market to 2017: Physical Delivery Methods
5.1 Introduction
5.1.1 Tattooing
5.1.2 Gene Gun
5.1.3 Ultrasound
5.1.4 Electroporation
5.1.5 Laser

6 Emerging Cancer Vaccines Market to 2017: Non-Physical Delivery Methods
6.1 Biological Gene Delivery Systems (Viral Vectors)
6.2 Non-Biological Gene Delivery Systems (Non-Viral Vectors)
6.2.1 Cationic Lipids/Liposomes
6.2.2 Polysaccharides and Cationic Polymers
6.2.3 Micro/Nano-particles
6.2.4 Cationic Peptides/CPP
6.2.5 Virus-Like Particles (VLPs) as an Efficient Delivery System
6.2.6 Delivery Systems in DC Vaccines
6.2.7 Delivery Systems in Protein/Peptide Vaccines
6.2.8 Mucosal Delivery System

7 Emerging Cancer Vaccines Market to 2017: Market Overview
7.1 Introduction
7.2 Revenue
7.3 Annual Cost of Vaccination
7.4 Target Population
7.4.1 Coverage Population
7.5 Unmet Needs
7.6 Drivers and Restraints
7.6.1 Drivers
7.6.2 Restraints

8 Emerging Cancer Vaccines Market to 2017: Therapeutic Landscape
8.1 Cervical Cancer Vaccines Market
8.1.1 Introduction
8.1.2 Unmet Needs
8.1.3 Revenue
8.1.4 Annual Cost of Vaccination
8.1.5 Target Population
8.1.6 Geographical Segmentation
8.1.7 Drivers and Restraints for the Cervical Cancer Vaccines Market
8.2 Prostate Cancer Vaccine Market
8.2.1 Introduction
8.2.2 Unmet Needs
8.2.3 Revenue
8.2.4 Annual Cost of Vaccination
8.2.5 Target Population
8.2.6 Geographical Segmentation
8.2.7 Drivers and Restraints for the Prostate Cancer Vaccines Market
8.3 Lung Cancer Vaccines Market
8.3.1 Introduction
8.3.2 Unmet Needs
8.3.3 Revenue
8.3.4 Annual Cost of Vaccination
8.3.5 Target Population
8.3.6 Geographical Segmentation
8.3.7 Drivers and Restraints for the Lung Cancer Vaccines Market
8.4 Pancreatic Cancer Vaccines Market
8.4.1 Introduction
8.4.2 Unmet Needs
8.4.3 Revenue
8.4.4 Annual Cost of Vaccination
8.4.5 Target Population
8.4.6 Geographical Segmentation
8.4.7 Drivers and Restraints for the Pancreatic Cancer Vaccines Market
8.5 Melanoma Vaccines Market
8.5.1 Introduction
8.5.2 Unmet Needs
8.5.3 Revenue
8.5.4 Annual Cost of Vaccination
8.5.5 Target Population
8.5.6 Geographical Segmentation
8.5.7 Drivers and Restraints for the Melanoma Vaccines Market

9 Emerging Cancer Vaccines Market to 2017: Geographical Landscape
9.1 The US
9.1.1 Revenue
9.1.2 Annual Cost of Vaccination
9.1.3 Target Population
9.2 Top Five Countries in Europe
9.2.1 Revenue
9.2.2 Annual Cost of Vaccination
9.2.3 Target Population
9.3 Japan
9.3.1 Revenue
9.3.2 Annual Cost of Vaccination
9.3.3 Target Population

10 Emerging Cancer Vaccines Market to 2017: Pipeline Analysis
10.1 Introduction
10.1.1 Research and Development Pipeline – Prostate Cancer Vaccines
10.1.2 Research and Development Pipeline – Lung Cancer Vaccines
10.1.3 Research and Development Pipeline – Pancreatic Cancer Vaccines
10.1.4 Research and Development Pipeline – Melanoma Vaccines
10.1.5 Research and Development Pipeline – Cervical Cancer Vaccines
10.2 R&D Trends
10.3 Profiles of Promising Drugs in the Emerging Cancer Vaccines Market to 2017
10.3.1 Stimuvax
10.3.2 OncoVEXGM-CSF
10.3.3 V503
10.3.4 GV1001
10.3.5 Lucanix
10.3.6 TG4010

11 Emerging Cancer Vaccines Market to 2017: Competitive Landscape
11.1 Marketed Cancer Vaccines
11.1.1 Gardasil
11.1.2 Cervarix
11.1.3 Provenge
11.2 Market Share Analysis
11.3 Competitive Profiling
11.3.1 Merck & Co., Inc.
11.3.2 Merck Serono
11.3.3 Amgen
11.3.4 GlaxoSmithKline
11.3.5 Dendreon
11.3.6 KAEL-Gemvax

12 Emerging Cancer Vaccines Market to 2017: Strategic Consolidations
12.1 Overview
12.1.1 M&A by Year
12.1.2 M&A by Geography
12.1.3 M&A by Value
12.1.4 M&A by Type
12.1.5 M&A by Company
12.1.6 Top 10 M&A
12.2 R&D Licensing Agreements
12.2.1 Deals by Year
12.2.2 Deals by Geography
12.2.3 Deals by Value
12.2.4 Deals by Company
12.2.5 Top 10 Deals
12.3 Co-Developments
12.3.1 Co-Developments by Year
12.3.2 Co-Developments by Geography
12.3.3 Co-Developments by Value
12.3.4 Top Five Co-Developments

13 Emerging Cancer Vaccines Market to 2017: Appendix
13.1 Market Definitions
13.2 Abbreviations
13.3 Research Methodology
13.3.1 Cancer Vaccine Development
13.3.2 Vaccine Delivery Methods
13.3.3 Market Overview
13.3.4 Therapeutic Landscape
13.3.5 Geographical Landscape
13.3.6 Pipeline Analysis
13.3.7 Competitive Landscape
13.3.8 Strategic Consolidations
13.4 Contact Us
13.5 Disclaimer
13.6 Sources

1.1 List of Tables

Table 1: Emerging Cancer Vaccines Market, Global, Revenue ($m), 2006-2010
Table 2: Emerging Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Table 3: Emerging Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2010
Table 4: Emerging Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Table 5: Emerging Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2006-2010
Table 6: Emerging Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Table 7: Cervical Cancer Vaccines Market, Global, Revenue ($m), 2006-2010
Table 8: Cervical Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Table 9: Cervical Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2010
Table 10: Cervical Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Table 11: Cervical Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2006-2010
Table 12: Cervical Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Table 13: Cervical Cancer Vaccines Market, Geographical Segmentation, Revenue ($m), 2006-2010
Table 14: Cervical Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
Table 15: Prostate Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Table 16: Prostate Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Table 17: Prostate Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Table 18: Prostate Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
Table 19: Lung Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Table 20: Lung Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Table 21: Lung Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Table 22: Lung Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
Table 23: Pancreatic Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Table 24: Pancreatic Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Table 25: Pancreatic Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Table 26: Pancreatic Cancer Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
Table 27: Melanoma Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Table 28: Melanoma Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Table 29: Melanoma Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Table 30: Melanoma Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
Table 31: Emerging Cancer Vaccines Market, The US, Revenue ($m), 2006-2010
Table 32: Emerging Cancer Vaccines Market, The US, Revenue Forecasts ($m), 2010-2017
Table 33: Emerging Cancer Vaccines Market, The US, Annual Cost of Vaccination ($), 2006-2010
Table 34: Emerging Cancer Vaccines Market, The US, Annual Cost of Vaccination ($), 2010-2017
Table 35: Emerging Cancer Vaccines Market, The US, Target and Coverage Population (‘000), 2006-2010
Table 36: Emerging Cancer Vaccines Market, The US, Target and Coverage Population (‘000), 2010-2017
Table 37: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Revenue ($m), 2006-2010
Table 38: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017
Table 39: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Annual Cost of Vaccination ($), 2006-2010
Table 40: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Annual Cost of Vaccination ($), 2010-2017
Table 41: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Target and Coverage Population (‘000), 2006-2010
Table 42: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Target and Coverage Population (‘000), 2010-2017
Table 43: Emerging Cancer Vaccines Market, Japan, Revenue Forecasts ($m), 2010-2017
Table 44: Emerging Cancer Vaccines Market, Japan, Annual Cost of Vaccination ($), 2010-2017
Table 45: Emerging Cancer Vaccines Market, Japan, Target and Coverage Population (‘000), 2010-2017
Table 46: Prostate Cancer Vaccines Market, Global, Pipeline Analysis, 2011
Table 47: Lung Cancer Vaccines Market, Global, Pipeline Analysis, 2011
Table 48: Pancreatic Cancer Vaccines Market, Global, Pipeline Analysis, 2011
Table 49: Melanoma Vaccines Market, Global, Pipeline Analysis, 2011
Table 50: Cervical Cancer Vaccines Market, Global, Pipeline Analysis, 2011
Table 51: Emerging Cancer Vaccines Market, Global, Pipeline Products, Merck & Co., Inc., 2011
Table 52: Emerging Cancer Vaccines Market, Global, Pipeline Products, Merck Serono S.A., 2011
Table 53: Emerging Cancer Vaccines Market, Global, Pipeline Products, Amgen, 2011
Table 54: Emerging Cancer Vaccines Market, Global, Pipeline Products, GSK, 2011
Table 55: Emerging Cancer Vaccines Market, Global, Pipeline Products, Dendreon, 2011
Table 56: Emerging Cancer Vaccines Market, Global, Pipeline Products, KAEL-GemVax, 2011
Table 57: Emerging Cancer Vaccines Market, Global, M&A by Year, 2004-2011
Table 58: Emerging Cancer Vaccines Market, Global, M&A by Company, 2004-2011
Table 59: Emerging Cancer Vaccines Market, Global, Top 10 M&A by Value ($m), 2004-2011
Table 60: Emerging Cancer Vaccines Market, Global, Deals by Year, 2004-2011
Table 61: Emerging Cancer Vaccines Market, Global, Deals by Company, 2004-2011
Table 62: Emerging Cancer Vaccines Market, Global, Top 10 Licensing Deals by Value ($m), 2004-2011
Table 63: Emerging Cancer Vaccines Market, Global, Co-Developments by Year, 2004-2011
Table 64: Emerging Cancer Vaccines Market, Global, Top Five Co-Developments by Value ($m), 2004-2011

1.2 List of Figures

Figure 1: Emerging Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2006-2017
Figure 2: Emerging Cancer Vaccines Market, Strategic Consolidations (%), 2004-2011
Figure 3: Emerging Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2006-2017
Figure 4: Emerging Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2017
Figure 5: Emerging Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2006-2017
Figure 6: Cervical Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2006-2017
Figure 7: Cervical Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2006-2017
Figure 8: Cervical Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2006-2017
Figure 9: Cervical Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2006-2017
Figure 10: Prostate Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Figure 11: Prostate Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Figure 12: Prostate Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Figure 13: Prostate Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010–2017
Figure 14: Lung Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Figure 15: Lung Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Figure 16: Lung Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Figure 17: Lung Cancer Vaccines Market, Geographical Segmentation, Revenue Forecasts ($m), 2010–2017
Figure 18: Pancreatic Cancer Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Figure 19: Pancreatic Cancer Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Figure 20: Pancreatic Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Figure 21: Pancreatic Cancer Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
Figure 22: Melanoma Vaccines Market, Global, Revenue Forecasts ($m), 2010-2017
Figure 23: Melanoma Vaccines Market, Global, Annual Cost of Vaccination ($), 2010-2017
Figure 24: Melanoma Cancer Vaccines Market, Global, Target and Coverage Population (‘000), 2010-2017
Figure 25: Melanoma Vaccines Market, Global, Geographical Segmentation, Revenue Forecasts ($m), 2010-2017
Figure 26: Emerging Cancer Vaccines Market, The US, Revenue Forecasts ($m), 2006-2017
Figure 27: Emerging Cancer Vaccines Market, The US, Annual Cost of Vaccination ($), 2006-2017
Figure 28: Emerging Cancer Vaccines Market, The US, Target and Coverage Population (‘000), 2006-2017
Figure 29: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017
Figure 30: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Annual Cost of Vaccination ($), 2006-2017
Figure 31: Emerging Cancer Vaccines Market, Top Five Countries of Europe, Target and Coverage Population (‘000), 2006-2017
Figure 32: Emerging Cancer Vaccines Market, Japan, Revenue Forecasts ($m), 2010-2017
Figure 33: Emerging Cancer Vaccines Market, Japan, Annual Cost of Vaccination ($), 2010-2017
Figure 34: Emerging Cancer Vaccines Market, Japan, Target and Coverage Population (‘000), 2010-2017
Figure 35: Emerging Cancer Vaccines Market, Global, R&D Pipeline by Phase (%), 2011
Figure 36: Emerging Cancer Vaccines Market, Global, R&D Pipeline by Indication (%), 2011
Figure 37: Prostate Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
Figure 38: Lung Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
Figure 39: Pancreatic Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
Figure 40: Melanoma Vaccines Market, Global, R&D Pipeline (%), 2011
Figure 41: Cervical Cancer Vaccines Market, Global, R&D Pipeline (%), 2011
Figure 42: Emerging Cancer Vaccines Market, Global, Market Share Analysis by Company (%), 2010
Figure 43: Emerging Cancer Vaccines Market, Merck & Co., Inc, SWOT Analysis, 2011
Figure 44: Emerging Cancer Vaccines Market, Merck Serono, SWOT Analysis, 2011
Figure 45: Emerging Cancer Vaccines Market, Amgen, SWOT Analysis, 2011
Figure 46: Emerging Cancer Vaccines Market, GSK, SWOT Analysis, 2011
Figure 47: Emerging Cancer Vaccines Market, Dendreon, SWOT Analysis, 2011
Figure 48: Emerging Cancer Vaccines Market, Global, M&A by Year, 2004-2011
Figure 49: Emerging Cancer Vaccines Market, Global, M&A by Geography (%), 2004-2011
Figure 50: Emerging Cancer Vaccines Market, Global, M&A by Value ($m), 2004-2011
Figure 51: Emerging Cancer Vaccines Market, Global, M&A by Type (%), 2004-2011
Figure 52: Emerging Cancer Vaccines Market, Global, M&A by Company, 2004-2011
Figure 53: Emerging Cancer Vaccines Market, Global, Deals by Year, 2004-2011
Figure 54: Emerging Cancer Vaccines Market, Global, Deals by Geography (%), 2004-2011
Figure 55: Emerging Cancer Vaccines Market, Global, Deals by Value ($m), 2004-2011
Figure 56: Emerging Cancer Vaccines Market, Global, Deals by Company, 2004-2011
Figure 57: Emerging Cancer Vaccines Market, Global, Co-Developments by Year, 2004-2011
Figure 58: Emerging Cancer Vaccines Market, Global, Co-Developments by Geography (%), 2004-2011
Figure 59: Emerging Cancer Vaccines Market, Global, Co-Developments by Value ($m), 2004-2011